Johnson & Johnson Secures Option to Acquire Sail Biomedicines for CAR-T Therapy Development

Johnson & Johnson has entered into a strategic agreement with Sail Biomedicines, involving an initial $785 million investment and an exclusive option to acquire the company for an additional $2.58 billion. This collaboration aims to advance in vivo CAR-T therapies, which could offer scalable and potentially curative treatments for immune-mediated diseases by reprogramming immune cells directly within the body. This significant financial commitment highlights the ongoing pursuit of innovative biotechnology solutions.